Molecular Formula | C22H17ClN6O |
Molar Mass | 416.86 |
Density | 1.474±0.06 g/cm3(Predicted) |
Melting Point | 205-206o C |
Boling Point | 757.8±60.0 °C(Predicted) |
Solubility | Soluble in DMSO (up to at least 25 mg/ml) |
Appearance | White solid. |
Color | White |
pKa | 10.05±0.10(Predicted) |
Storage Condition | -20°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
In vitro study | IPI-145 inhibited murine/human B cell proliferation with an EC50 of 0.5 nM/0.5 nM and also inhibited human T cell proliferation with an EC50 of 9.5 nM. |
In vivo study | IPI-145 mice and rats were treated orally at a dose of 10 mg/kg with good pharmacokinetics, with Cmax and ACC of 390 ng/mL and 137 ng • h/mL, respectively. IPI-145 (10 mg/kg) is effective in a murine DTH model with ~ 50% ear swelling. IPI-145 (10 mg/kg) is effective in a dose-dependent manner in a rat collagen-induced arthritis (CIA) model. IPI-145 acts on the rat CIA model to prevent inflammation and protect joint bone and cartilage. IPI-145 (10 mg/kg,QD) was effective in adjuvant-induced polyarthritis in rats. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.399 ml | 11.994 ml | 23.989 ml |
5 mM | 0.48 ml | 2.399 ml | 4.798 ml |
10 mM | 0.24 ml | 1.199 ml | 2.399 ml |
5 mM | 0.048 ml | 0.24 ml | 0.48 ml |